Get the Stockscreener App
2.058
4.23%
-0.112
Tc Biopharm Holdings Plc Adr stock is traded at $2.058, with a volume of 51,606.
It is down -4.23% in the last 24 hours and up +651.61% over the past month.
TC BioPharm (Holdings) PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapy products that are based on its proprietary allogeneic gamma delta T (abbreviated as GD-T) cell platform. Harnessing the innate ability of GD-Ts has enabled the company to develop a range of clinical-stage cell therapies designed to combat cancer and viral infection.
See More
Previous Close:
$2.17
Open:
$2.12
24h Volume:
51,606
Relative Volume:
0.04
Market Cap:
$1.11M
Revenue:
$4.60M
Net Income/Loss:
$-6.25M
P/E Ratio:
-0.0291
EPS:
-70.6412
Net Cash Flow:
$-15.38M
1W Performance:
-16.87%
1M Performance:
+651.61%
6M Performance:
-36.64%
1Y Performance:
-80.69%
1-Day Range:
$2.00
$2.13
1-Week Range:
$1.91
$2.69
52-Week Range:
$0.20
$26.16
Tc Biopharm Holdings Plc Adr Stock (TCBP) Company Profile
Name
Tc Biopharm Holdings Plc Adr
Sector
Industry
Phone
01414337557
Address
MAXIM 1, HOLYTOWN
Compare TCBP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TCBP
Tc Biopharm Holdings Plc Adr
|
2.058 | 1.11M | 4.60M | -6.25M | -15.38M | -70.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
475.45 | 121.85B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
696.38 | 76.83B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
616.76 | 37.96B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.92 | 30.69B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beone Medicines Ltd Adr
|
267.77 | 29.71B | 3.32B | -860.46M | -1.04B | -8.32 |
Tc Biopharm Holdings Plc Adr Stock (TCBP) Latest News
What Lies Ahead For TC BioPharm (Holdings) plc ADR (NASDAQ: TCBP) In 2025? - Stocks Register
TC Biopharm completes initial Cohort B patient dosing in ACHIEVE trial - MSN
TC BioPharm Announces ADS Ratio Change - TipRanks
TC BioPharm (Holdings) plc ADR (TCBP) Stock: Uncovering 52-Week Market Trends - The InvestChronicle
TC BioPharm reports progress in AML treatment trial - Investing.com
TC BioPharm (Holdings) plc ADR (TCBP): A Technical Analysis - The News Heater
Ratios Reveal: Breaking Down TC BioPharm (Holdings) plc ADR (TCBP)’s Financial Health - The Dwinnex
Quarterly Snapshot: Quick and Current Ratios for ScanTech AI Systems Inc (STAI) - The Dwinnex
Upcoming Stock Splits This Week (February 10 to February 14) – Stay Invested - Markets Insider
Check Out TC BioPharm (Holdings) plc ADR (TCBP)’s Trade Data Rather Than the Analysts’ Views - SETE News
TC BioPharm's Major ADS Restructure: What This 1:20 Ratio Change Means For Your Holdings - StockTitan
TC BioPharm (Holdings) plc ADR (TCBP) Stock: A Year of Highs and Lows in the Market - The InvestChronicle
TC Biopharm Faces Potential Nasdaq Delisting Due to Bid Price Non-Compliance - TipRanks
TC Biopharm Announces Special Stock Dividend and Temporary Trading Halt - TipRanks
TC BioPharm advances in acquisition strategy - Investing.com India
What Analysts Think About TC BioPharm (Holdings) plc ADR (NASDAQ: TCBP)’s Potential Raise - Stocks Register
TC BioPharm Approves Key Resolutions to Enhance Strategic Flexibility - TipRanks
No Stopping Argo Blockchain Plc ADR (NASDAQ: ARBK)’s Stock Plunged? - Stocks Register
NIO Inc ADR (NYSE: NIO) Stock Forecast: Could Pass $8 In A Year - Stocks Register
If You Don’t Buy Safe Pro Group Inc (NASDAQ: SPAI) Now, You’ll Regret It Later - Stocks Register
Would I Buy Opendoor Technologies Inc (NASDAQ: OPEN) Stock At Any Time In The Future? - Stocks Register
Tempest Therapeutics Inc (NASDAQ: TPST) Investors Should Be Worried About This. - Stocks Register
Where Do Analysts See Gamestop Corporation (NYSE: GME) Heading? - Stocks Register
TC BioPharm Advances Strategic Financial Initiative with New ADS Offering - TipRanks
TC BioPharm Announces Key Shareholder Meeting - TipRanks
TC Biopharm files $100M mixed securities shelf - TipRanks
TC Biopharm Faces Financial Strains Amid Rising Costs - TipRanks
TC Biopharm awarded funding of $250,000 from G-Rex Grant Program - TipRanks
TC BioPharm advances cancer therapy trials, raises $8M By Investing.com - Investing.com South Africa
TC BioPharm advances cancer therapy trials, raises $8M - Investing.com India
TC Biopharm refutes social media claim, remains compliant with Nasdaq rules - TipRanks
TC BioPharm denies Nasdaq delisting rumors - Investing.com
TC Biopharm enters research pact with Dr. Carlos Maluquer de Motes - TipRanks
United States shares mixed at close of trade; Dow Jones Industrial Average down 0.80% - Investing.com India
TC Biopharm (Holdings) PLC – ADR trading halted, volatility trading pause - TipRanks
U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.80% - Investing.com
TCBP Stock Update: TC BioPharm (Holdings) plc ADR’s Banking’s Market Struggles and Potential Opportunities - The InvestChronicle
TC Biopharm announces artificial intelligene initiative with Carnegie Mellon - TipRanks
TCBP Announces Site Opening of Guys and St. Thomas Hospital - StockTitan
TC Biopharm announces first patient completes full dose regimen in ACHIEVE trial - TipRanks
TC BioPharm to start preclinical studies on monkeypox therapy - Investing.com India
TC Biopharm intends to launch preclinical study for treatment of Mpox - TipRanks
TC BioPharm to begin monkeypox treatment studies - Investing.com
TCBP’s Market Moves: -77.03% YTD Growth, -42.22% 6-Month loss, 68.52% in 30 Days - The InvestChronicle
TC BioPharm (Holdings) plc ADR (TCBP)’s stock rises to 7.28 per share - US Post News
TC Biopharm doses five new patients in the ACHIEVE Phase 2b trial in UK - TipRanks
TC Biopharm Unveils New Pre-Funded Warrant - TipRanks
Was there any good news for TC BioPharm (Holdings) plc ADR (TCBP) stock in the last session? - US Post News
Tc Biopharm Holdings Plc Adr Stock (TCBP) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.44%
0.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):